Marco Bolis

This study identifies miR-29 as a key regulator of age-related epigenetic changes, showing it promotes fidelity but reduces plasticity in methylome maintenance and adaptation.

A transcript-resolution prostate cancer atlas, built by uniformly reprocessing public RNA-seq cohorts, links isoform switches in cancer genes to oncogenic pathway activity and some to CRPC survival.

This study identifies a SWI/SNF-targeting therapy effective against a double-negative prostate cancer subtype, showing it reduces viability in both AR-dependent and WNT-dependent models.

This study shows that loss of EHF promotes cell plasticity, transformation, and androgen independence in early prostate cancer by disrupting lineage integrity and activating downstream pathways.

This study shows that disrupting FOXA1 and FOXA2 disrupts oncogenic programs in both AR-positive and AR-negative prostate cancers.

This study identifies TRIM24 as a target for preventing prostate cancer progression by degrading it to counteract AR inhibition adaptation and tumor relapse.